Loading...
Loading...
PALI| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 3,848.0K |
| Operating I/L | -3,848.0K |
| Other Income/Expense | 128.0K |
| Interest Income | 0.0K |
| Pretax | -3,720.0K |
| Income Tax Expense | -1,039.0K |
| Net Income/Loss | -2,681.0K |
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of oral therapies targeting diseases related to gastrointestinal mucosal barrier breakdown. Their lead candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress caused by reduced blood flow, infections, or surgery.
